Cantor Fitzgerald maintains Amgen stock rating ahead of earnings By Investing.com

Amgen reported a 77% proptosis response in its Phase 3 subcutaneous TEPEZZA trial versus 19.6% for placebo, prompting William Blair and RBC to reiterate Outperform and supporting Cantor Fitzgerald's Neutral $350 price target. Cantor Fitzgerald notes AMGN trades at a P/E of 23.85 and PEG of 0.27 and views the April 30, 2026 Q1 earnings as a favorable setup with expected commercial beats (Repatha, Uplizna, Krystexxa, Imdelltra) but limited top-line upside due to seasonal headwinds. Key downside risks include incremental MariTide data developments and potential updates on IRS tax litigation. The clinical data is a meaningful positive catalyst for AMGN and weighs on competitor Viridian, but litigation and pipeline uncertainties temper near-term upside.

Analysis

Amgen is positioned to convert recent clinical momentum into a durable commercial uplift if management can operationalize a shift toward lower-cost, subcutaneous delivery at scale. That distribution change is a second-order demand amplifier: it reduces per-patient administration cost, broadens site-of-care options (ambulatory clinics, specialty retailers), and raises the effective addressable market for launches—the kind of margin-accretive mix shift that translates to high-conviction free cash flow upside over 12-24 months rather than a one-quarter bump.

The main near-term frictions are execution and optionality erosion: manufacturing scale-up for new formats, payer contract resets following label changes, and any adverse late-breaking information on contentious pipeline programs. These are binary to binary-plus outcomes — a smooth rollout boosts consensus EPS by mid-single-digit percent over the next 12 months; a regulatory or manufacturing snag can erase that and compress multiples because the company is priced for steady execution.

From a competitive angle, incumbent large-cap biologics developers and CDMOs stand to gain share while smaller, single-product biotechs face increased displacement risk. Clinically equivalent SC formulations lower switching costs for physicians and payers, favoring firms with national commercial footprints and integrated specialty sales channels; expect accelerated share consolidation in relevant therapeutic niches over 6–18 months.

Market sentiment appears to be queuing a positive earnings beat but is underpricing execution tail risk and the timing of payor accommodations. If the next quarter shows the expected commercial cadence without surprises, the move is likely underdone; conversely, a modest operational miss could trigger an outsized multiple re-rating because much of the upside is front-loaded into expectations.

Key Decisions for Investors

• Long-core equity: Initiate a 3–6% position in AMGN on market weakness, target 15–25% upside over 6–12 months, stop at 8% below entry to protect against binary execution failures.
• Options asymmetric: Buy 6–9 month AMGN calls (≈25–30% OTM) sized at 0.5–1% notional and fund with short-term (30–60 day) covered-call sales post-earnings to monetize IV — goal 3:1 reward-to-risk if SC commercialization proves durable.
• Pair trade for idiosyncratic hedge: Long AMGN / short VRDN (equal dollar) to express structural share consolidation; expected outcome is AMGN outperformance by 8–15% over 6–12 months if incumbency wins, with pair stop if VRDN rallies >20%.
• Event-driven hedge: Buy short-dated puts (15–20 delta) into the next quarterly report to limit downside from an operational miss; cost should be <1% of portfolio and caps drawdown from a negative surprise.
• Liquidity/scale play: Add small exposures to high-quality CDMOs and specialty distributors (through ETFs or select names) on pullbacks—these should capture secular flow-through from increased SC adoption over 12–24 months, offering 12–18% upside if adoption accelerates.